Get the CPRX Research Report and
Also Receive Our Top Trades for 2017!

Catalyst Pharmaceuticals, Inc.

On June 26, 2017, Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, announced that the company has been added to the broad-market Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions posted June 9. (See Research Report)
Download Research Report
on CPRX Now